Literature DB >> 6329862

Ranitidine in reflux oesophagitis. A double-blind placebo-controlled study.

K R Hine, G K Holmes, V Melikian, M Lucey, P D Fairclough.   

Abstract

This study was designed to assess the effect of ranitidine on patients with symptomatic oesophageal reflux. In a double-blind comparative trial in 46 patients a twice daily dose of 150 mg ranitidine was compared with placebo. Relief of pain, endoscopic healing and histological improvement were significantly better in those treated with ranitidine. Thus, ranitidine is of value in the management of patients with reflux oesophagitis and may prevent the development of peptic stricture.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329862     DOI: 10.1159/000199020

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

Review 1.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

2.  Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis.

Authors:  G Vantrappen; L Rutgeerts; P Schurmans; J L Coenegrachts
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

Review 3.  Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

Authors:  N J Bell; R H Hunt
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

4.  Meta-Analyses of Cisapride, Omeprazole and Ranitidine in the Treatment of GORD: Implications for Treating Patient Subgroups.

Authors:  M Iskedjian; T R Einarson
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 5.  Pharmacological management of gastro-oesophageal reflux disease.

Authors:  E C Klinkenberg-Knol; H P Festen; S G Meuwissen
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.